Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies

Launched by UNIVERSITY HOSPITAL, ANTWERP · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how certain biological processes, specifically ferroptosis (a type of cell death related to iron), might contribute to organ failure in critically ill patients. When patients come to the intensive care unit (ICU) with serious conditions like severe infections, trauma, or brain hemorrhages, the goal is to find out what is causing their organs to fail. By measuring specific markers in the blood and other fluids, researchers hope to understand if targeting ferroptosis can lead to new treatments that help prevent or improve organ failure.

To participate in this study, patients must be admitted to the ICU at UZA and expected to stay for at least 48 hours, typically due to conditions like sepsis or severe injuries. Participants will have an arterial line placed for blood sampling, which makes it easier to collect the necessary samples. It’s important to note that patients or their relatives must agree to participate, and those who have recently had major surgery and are not expected to stay in the ICU for a long time will not be included. This trial is an exciting step toward discovering new ways to help critically ill patients recover better and faster.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to the ICU of UZA
• • Critically ill and predicted to be hospitalised in the ICU for \> 48 hours (i.e. mostly patients admitted for sepsis, trauma, haemorrhagic shock, neurological catastrophe ... which means at risk to develop mono-or multiple organ failure)
• • With arterial line in place (for blood sampling)
• Exclusion Criteria:
• • Refusal of consent by patient or closest relative
• • Postoperative patients after major surgery in whom prolonged ICU stay is not foreseen (i.e. elective cardiac surgery